Esketamine-Associated Lower Urinary Tract Symptoms Suggestive of Bladder Overactivity in Treatment-Resistant Depression: A Case Report
This case report describes a patient with treatment-resistant depression who developed non-inflammatory lower urinary tract symptoms suggestive of bladder overactivity shortly after starting intranasal esketamine, which resolved upon spacing the treatment frequency.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Depression is a heavy burden that can make the world feel gray and unmovable, but for some people, standard treatments simply do not work. These individuals, who suffer from what doctors call treatment-resistant depression, often find themselves without hope after trying many different medications. In recent years, a new therapy has emerged to help this specific group: a spray containing a drug called esketamine. This medicine works differently than older antidepressants. Instead of slowly adjusting the brain's mood chemicals over weeks, it acts quickly on a system involved in how brain cells talk to one another, often bringing relief within hours or days. While this treatment has been a lifeline for many, scientists are still learning about every possible side effect it might cause. Just as a powerful tool can have unexpected consequences, researchers are carefully watching to see if this rapid-acting spray affects other parts of the body, particularly the bladder, which is known to be sensitive to similar drugs when used in different ways.
The story of one patient illustrates a rare but important discovery about this treatment. A fifty-year-old man, who had struggled with severe depression for a decade, began using the nasal spray after other medications failed to help him. His life had become difficult; he spent most of his days lying down, unable to work or enjoy his family, and he carried a constant, heavy sense of hopelessness. When the doctors started the esketamine treatment, his mood began to lift remarkably fast. Within a month, he felt a significant change, and after nine months, he reached a point where his depression symptoms had completely disappeared. He was able to return to his job and drive without the terrifying thoughts that had once haunted him. However, shortly after starting the second dose of the spray, a new and troubling problem appeared. He began to feel a sudden, intense need to urinate, accompanied by discomfort in his lower belly, even though he had no pain when passing urine and no fever.
Doctors first suspected a common bladder infection, but tests told a different story. Blood work and urine samples showed no signs of bacteria, inflammation, or infection. An ultrasound of his kidneys and bladder looked normal, and his blood tests were healthy. The only thing that seemed out of place was the timing of his symptoms, which appeared right after he started the new medication. Because the standard infection-fighting medicines did not help, and because the tests ruled out a typical infection, the medical team looked closer at the drug itself. They tried a different medication to calm the bladder, which helped a little, but the symptoms only went away completely when they changed how often the patient received the esketamine. By spacing the treatments out to once a week instead of more frequently, the urinary urgency vanished. The patient continued his weekly treatments for a full year without the problem returning, and his depression remained in remission.
This case suggests that the drug can sometimes cause the bladder to feel overactive, creating a strong urge to go even when the bladder is not full, but without causing the damage or inflammation seen in more severe bladder conditions. The researchers believe this happens because the drug temporarily changes how the nerves in the brain and bladder communicate, rather than by injuring the bladder tissue itself. This is different from what is seen in people who misuse a similar drug recreationally, where long-term, high-dose use can lead to serious, permanent damage to the bladder lining. In this patient's case, the issue was linked to how often he received the dose during the initial, intense phase of treatment. When the frequency was lowered, the symptoms stopped. The doctors used a standard scale to evaluate the likelihood that the drug caused the problem, and the score indicated a probable connection.
The significance of this finding lies in what it means for patients and doctors. If a patient develops these urinary symptoms, it does not necessarily mean they must stop a treatment that is saving their life. Instead, it suggests that adjusting the schedule of the doses might be enough to solve the problem. This case highlights that while the drug is generally safe, it can affect the urinary system in a way that is reversible and manageable. It serves as a reminder to doctors to listen carefully to patients who report these specific symptoms, so they can adjust the treatment plan rather than abandoning a therapy that is working well for the depression. For the patient in this story, the solution allowed him to keep the benefits of the treatment while living without the distress of the urinary symptoms, proving that careful monitoring can help navigate the complex balance between healing the mind and protecting the body.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.